Related Experiment Video

Updated: Jun 16, 2026

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells
06:29

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells

Published on: July 30, 2020

Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer

Christopher P Gully1, Fanmao Zhang, Jian Chen

  • 1Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Molecular Cancer
|February 24, 2010
PubMed
Abstract

Insights

AZD1152 effectively targets Aurora B kinase in breast cancer cells, leading to tumor suppression and apoptosis. This study reveals a new mechanism of Aurora B regulation, offering insights for metastatic breast cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Aurora B kinase is a key mitotic regulator overexpressed in various cancers, making it a potential therapeutic target.
  • AZD1152 is a prodrug for AZD1152-HQPA, a selective Aurora B kinase inhibitor with preclinical efficacy in several cancers.
  • The efficacy of AZD1152 in breast cancer, a leading cause of cancer mortality, remained unevaluated.

Purpose of the Study:

  • To evaluate the antineoplastic activity of AZD1152-HQPA in human breast cancer models.
  • To elucidate the mechanism of action of AZD1152-HQPA in breast cancer.
  • To explore the potential of AZD1152 for treating metastatic breast cancer.

Main Methods:

  • In vitro testing on six human breast cancer cell lines, including HER2-overexpressing lines.
  • In vivo studies using breast cancer cell xenograft and metastatic models.
  • Analysis of Aurora B kinase activity, cell cycle progression, apoptosis, and protein turnover.

Main Results:

  • AZD1152-HQPA demonstrated potent antineoplastic effects, inhibiting Aurora B kinase activity and inducing mitotic catastrophe, polyploidy, and apoptosis in breast cancer cells.
  • AZD1152 significantly suppressed tumor growth in xenograft models and reduced pulmonary metastasis.
  • Aurora B kinase protein levels decreased post-treatment, mediated by accelerated ubiquitination and protein turnover.

Conclusions:

  • AZD1152 is a promising antineoplastic agent for breast cancer treatment.
  • A novel posttranscriptional regulatory mechanism of Aurora B kinase was identified following AZD1152 treatment.
  • Findings provide a basis for designing dosing regimens for AZD1152 in metastatic breast cancer therapy.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...